pBFS Guided rTMS Over DMPFC for Treatment-Resistant Depression

Major Depressive Disorder Clinical Trial

Official title:

Personalized Brain Functional Sector-guided rTMS Therapy Targeting DMPFC for Treatment-resistant Depression

Clinical Trial Details — Status: Recruiting

Administrative data

• NCT number: NCT05948839
• Other study ID #: CPLMDDDM150
• Status: Recruiting
• Phase: N/A
• Start date: July 11, 2023
• Est. completion date: September 1, 2024

Study information

• Verified date: December 2023
• Source: Changping Laboratory
• Contact: Meiling Li, Ph.D.
• Phone: 010-80726688
• Email: meilingli[@]cpl.ac.cn
• Is FDA regulated: No
• Study type: Interventional

Clinical Trial Summary

Investigators aim to evaluate the safety and efficacy of pBFS-guided rTMS therapy targeting DMPFC for patients with treatment-resistant depression

Description:

Repetitive transcranial magnetic stimulation (rTMS) is an established therapy for treatment-resistant depression. The dorsomedial prefrontal cortex (DMPFC), which serves as a connection intermediary of the aberrant functional network in cognitive control and rumination in depression, has been shown to be highly correlated with disease manifestations and post-treatment improvements through several studies involving neuroimaging and brain injury. Research has shown that the response of DMPFC to rTMS is more subject to improving the dimensions of anxiety and insomnia in depression. Therefore, exploring the novel target DMPFC is also beneficial for distinguishing disease dimensions in the future, thereby enabling personalized treatment and improving clinical treatment efficacy.

After being informed about the study and potential risks. All patients giving written informed consent will undergo a screening period to determine eligibility for study entry. At week 0, patients who meet the eligibility requirements will be randomized in a double-blind manner in a 2:1 ratio to the active rTMS group, or sham-control group. Then all participants will undergo a 21-day rTMS modulation and a three- and nine-week follow-up visit.

Recruitment information / eligibility

• Status: Recruiting
• Enrollment: 170
• Est. completion date: September 1, 2024
• Est. primary completion date: June 1, 2024
• Accepts healthy volunteers: No
• Gender: All
• Age group: 18 Years to 65 Years

Eligibility

Inclusion Criteria:

• Hospitalized/outpatient patients aged 18-65 years (inclusive), male or female.

• Meet the diagnostic criteria of DSM-5(Diagnostic and Statistical Manual of Mental Disorders, Fifth Edition) for depression disorder without psychotic symptoms, and currently experiencing a recurrence episode.

• Total HAMD17 score =20 and total MADRS score =25 before randomization.

• Inadequate response to at least one antidepressant trial of adequate doses and duration.

• A stable antidepressant regimen for at least 4 weeks at a dose not lower than the prescribed range of drug use before randomization.

• Voluntarily participate in the trial and sign informed consent. Able to comply with the planned visit, examination and treatment plan, and other study procedures.

Exclusion Criteria:

• Meet DSM-5 diagnostic criteria for other mental disorders (such as schizophrenia spectrum disorders, bipolar and related disorders, neurodevelopmental disorders, neurocognitive disorders, or depressive disorders due to substances and/or medications, depressive disorders due to other medical problems, etc.);

• Patients with a cardiac pacemaker, cochlear implant, or other metal foreign body and any electronic equipment implanted in the body, patients with claustrophobia and other contraindications to magnetic resonance scanning, and patients with contraindications to rTMS treatment;

• Patients with serious or unstable diseases of the cardiovascular, liver, kidney, blood, endocrine, neurological system, and other systems or organs, especially those with organic brain diseases (such as ischemic stroke, cerebral hemorrhage, brain tumor, etc.) and a history of severe brain trauma as judged by the researcher;

• History of epilepsy (presence of at least 2 uninduced seizures more than 24 hours apart, or diagnosis of the epileptic syndrome, or seizures within the past 12 months); Or currently received medications or other treatments that will lower the seizure threshold;

• History of ECT, rTMS, VNS, DBS, tDCS, light therapy, or other physical therapy related to mental illness within 3 months;

• Currently receiving or planning to start formal cognitive or behavioral therapy, or systemic psychological therapy (interpersonal therapy, dynamic therapy, cognitive behavioral therapy, etc.) during the trial.

• Substance abuse or dependence (including alcohol, drugs, and other psychoactive substances) in the past 1 year;

• Female of childbearing potential who plans to become pregnant during the trial.

• Female that is pregnant or breastfeeding.

• Patients in any clinical trials of other drugs or physical therapy within 1 month before the screening.

• First-degree relatives have bipolar affective disorder.

• There is a significant risk of suicide (MADRS item 10 = 5).

• Difficulty or inability to engage in normal communication, understand or follow instructions, and cooperate with treatment and evaluators.

• Investigators think that was inappropriate to participate.

Related Conditions & MeSH terms

• Depression
• Depressive Disorder
• Depressive Disorder, Major
• Depressive Disorder, Treatment-Resistant
• Major Depressive Disorder
• Treatment Resistant Depression

Intervention

Device:
• active rTMS treatment
Participants will receive 3 sessions per day of 1800 pulses per session, lasting for 21 days. Individualized targets will be generated using the pBFS method.
• sham rTMS treatment
The parameters in the sham arms are the same as the active stimulation groups. Stimulation was delivered by the same device as the active group fitted with a sham coil.

Locations

Country	Name	City	State
China	Hebei Mental Health Center	Baoding	Hebei
China	Shandong Daizhuang Hospital	Jining
China	The Second Affiliated Hospital of Xinxiang Medical University	Xinxiang

Sponsors (5)

Lead Sponsor	Collaborator
Changping Laboratory	Hebei Mental Health Center, Shandong Daizhuang Hospital, The Second Affiliated Hospital of Xinxiang Medical University, West China Hospital

Country where clinical trial is conducted

China, 

Outcome

Type	Measure	Description	Time frame	Safety issue
Primary	Change in Montgomery-Asberg Depression Rating Scale (MADRS) scores from baseline to Immediate Post-treatment	The Montgomery-Asberg Depression Rating Scale (MADRS) is a validated instrument stratifying the severity of depressive episodes in adults. The MADRS has an overall score ranging from 0 (no depression) to 60 (worst depression).	Baseline and Day 21(Immediate Post-treatment)]
Secondary	Remission and response rates were estimated using Montgomery-Asberg Depression Rating Scale(MADRS)	The response is defined as a symptom improvement of =50% and remission is defined as a score =10 on MADRS	Baseline, Day 21 (Immediate Post-treatment)
Secondary	Remission and response rates were estimated using Hamilton Depression Rating Scale (HAMD-17)	The Hamilton Depression Rating Scale (HAMD) is the most widely used clinician-administered depression assessment scale. The HAMD-17 version consists of 17 items,and has an overall score ranging from 0 (no depression) to 52 (worst depression). Higher scores represent higher depression severity. The response is defined as a symptom improvement of =50% and remission is defined as a score =7 on HAMD-17	Baseline, Day 21 (Immediate Post-treatment)
Secondary	Changes in the MADRS from baseline to each visit	The MADRS has an overall score ranging from 0 (no depression) to 60 (worst depression). Higher scores represent higher depression severity.	Baseline, Day 21 (Immediate Post-treatment), 3-week Post-treatment, 9-week Post-treatment
Secondary	Changes in the HAMD-17 from baseline to each visit	The Hamilton Depression Rating Scale (HAMD) is the most widely used clinician-administered depression assessment scale. The HAMD-17 version consists of 17 items,and has an overall score ranging from 0 (no depression) to 52 (worst depression). Higher scores represent higher depression severity.	Baseline, Day 21 (Immediate Post-treatment), 3-week Post-treatment, 9-week Post-treatment
Secondary	cognitive changes from baseline to day 21(Immediate Post-treatment)	Cognitive scores are measured using Chinese brief cognitive test (C-BCT), including Digit Symbol Substitution Test (DSST), continuous performance test (CPT), Trail-Making Test (TMT), Digit Span Test (DST)	Baseline, Day 21 (Immediate Post-treatment)